Obalon Announces Fourth Quarter and Full Year 2017 Financial Results
March 05, 2018 15:01 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Schedules Fourth Quarter and Year End 2017 Financial Results Conference Call for March 5, 2018 at 5:00 p.m. Eastern Time
March 05, 2018 09:01 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
February 20, 2018 07:01 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today announced the Audit Committee has completed its investigation into a purported whistleblower complaint and...
Obalon Announces Termination of Public Offering of Common Stock
January 23, 2018 09:13 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (the “Company” or “Obalon”) (NASDAQ:OBLN) today announced the termination of the underwriting agreement and cancellation of its...
Obalon Therapeutics Prices Public Offering of Common Stock
January 18, 2018 22:00 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled...
Obalon Therapeutics Announces Proposed Public Offering of Common Stock
January 16, 2018 16:01 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled...
Obalon Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Full Year 2017
January 05, 2018 08:00 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today reported that it achieved preliminary, unaudited revenue of approximately $3.9 million for the fourth...
Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time
January 04, 2018 17:15 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Upcoming Conference Presentations
November 06, 2017 08:46 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...
Obalon Announces Third Quarter 2017 Financial Results
November 03, 2017 07:29 ET
|
Obalon Therapeutics, Inc.
SAN DIEGO, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...